Neoadjuvant chemotherapy did not improve survival over upfront pancreatoduodenectomy in resectable pancreatic head cancer, in a single-center retrospective cohort.
- Overall survival and recurrence-free survival were similar across upfront surgery, neoadjuvant gemcitabine plus nab-paclitaxel, and neoadjuvant gemcitabine plus S-1.
- A preoperative CA19-9 of 37 U/ml or higher was independently linked to worse overall survival.
- Retrospective single-center cohort of 196 patients who underwent pancreaticoduodenectomy from 2012 to 2022, with groups of 112, 45, and 39.
Surgeons should not switch to neoadjuvant therapy on the basis of trial survival data alone, since this cohort did not reproduce that benefit. Preoperative CA19-9 may help identify patients with poorer prognosis who need closer selection for neoadjuvant treatment.
Journal Article by Kimura K, Sato S (…) Hirano S et 9 al. in J Gastrointest Oncol
© AME Publishing Company.